Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spark Therapeutics Inc.

www.sparktx.com

Latest From Spark Therapeutics Inc.

Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.

Pricing Strategies Gene Therapy

Manufacturing Cures: Infrastructure Challenges Facing Cell And Gene Therapy Developers

As more regenerative medicine products approach clinical testing and commercialization, stakeholders in the field are increasingly pressed to address substantial challenges, including pricing and reimbursement, GMP manufacturing, and clinical availability, and patient accessibility to these life changing therapies.

Market Intelligence Regenerative Medicine

Spotlight on Q1 Pharma M&A Merry-Go-Round

Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.

M & A Market Intelligence

A New Drug Price Milestone

Much like Genzyme’s Ceredase did two decades ago, Novartis’ Zolgensma is setting a new pricing benchmark. The first million-dollar product is launching in the US and it will actually cost more than $2 million.

Pricing Debate Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Spark Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Spark Therapeutics Inc.
  • Senior Management
  • Jeffrey D Marrazzo, CEO
    Stephen Webster, CFO
    Katherine A High, MD, Pres. & Head, R&D
    Daniel R Faga, CBO
    Frederico Mingozzi, PhD, CSO
  • Contact Info
  • Spark Therapeutics Inc.
    Phone: (215) 220-9300
    3737 Market St.
    Philadelphia, PA 19104
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register